Search

Search bills, members, committees and pages...

H.R. 4993

U.S. HouseIn House Committee

Summary

H.R. 4993, the Joe Fiandra Access to Home Infusion Act of 2025, was introduced in the House on Aug 19, 2025 by Rep. Brian Fitzpatrick (R) with 6 co-sponsors. It last saw action on Dec 10, 2025: Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.


Record

Text

H.R. 4993 has 6 co-sponsors.

hb4993/introduced-in-house.txt
119 HR 4993 IH: Joe Fiandra Access to Home Infusion Act of 2025
U.S. House of Representatives
2025-08-19
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
I 119th CONGRESS 1st Session H. R. 4993 IN THE HOUSE OF REPRESENTATIVES August 19, 2025 Mr. Fitzpatrick (for himself, Mr. Dunn of Florida , and Mr. Soto ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL
To amend title XVIII of the Social Security Act to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under the Medicare program.
1.
Short title
This Act may be cited as the Joe Fiandra Access to Home Infusion Act of 2025 .
2.
Medicare coverage of external infusion pumps and non-self-administrable home infusion drugs
(a)
In general
Section 1861(n) of the Social Security Act ( 42 U.S.C. 1395x(n) ) is amended by adding at the end the following new sentence:
Beginning with the first calendar quarter beginning on or after the date that is 1 year after the date of the enactment of this sentence, an external infusion pump and associated home infusion drug (as defined in subsection (iii)(3)(C)) or other associated supplies that do not meet the appropriate for use in the home requirement applied to the definition of durable medical equipment under section 414.202 of title 42, Code of Federal Regulations (or any successor to such regulation) shall be treated as meeting such requirement if each of the following criteria is satisfied:
(1)
The prescribing information approved by the Food and Drug Administration for the home infusion drug associated with the pump instructs that the drug should be administered by or under the supervision of a health care professional.
(2)
A qualified home infusion therapy supplier (as defined in subsection (iii)(3)(D)) administers or supervises the administration of the drug or biological in a safe and effective manner in the patient’s home (as defined in subsection (iii)(3)(B)).
(3)
The prescribing information described in paragraph (1) instructs that the drug should be infused at least 12 times per year—
(A)
intravenously or subcutaneously; or
(B)
at infusion rates that the Secretary determines would require the use of an external infusion pump.
.
(b)
Cost sharing notification
The Secretary of Health and Human Services shall ensure that patients are notified of the cost sharing for electing home infusion therapy compared to other applicable settings of care for the furnishing of infusion drugs under the Medicare program.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-08-19
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Introduced in House Aug 19, 2025

hb4993/introduced-in-house.md

Shown Here:
Introduced in House (08/19/2025)

Joe Fiandra Access to Home Infusion Act of 2025

This bill provides for Medicare coverage of certain home infusion drugs that are administered by health care professionals at a beneficiary’s home.

Specifically, the bill provides for coverage of external infusion pumps and associated home infusion drugs for which (1) the prescription requires that the drug be administered by or under the supervision of a health care professional, (2) a qualified home infusion therapy supplier administers or supervises the administration of the drug at the beneficiary's home, and (3) the prescription requires that the drug be infused at least 12 times per year in a manner that requires the use of an external infusion pump.

Sponsors

Rep. Brian Fitzpatrick (R) sponsors H.R. 4993, and 6 members have co-sponsored it, 2 of them from the day it was introduced.

Committees

H.R. 4993 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means
Ways and Means
Markup By · Dec 10, 2025 · 1,160 Bills
Energy and Commerce
Energy and Commerce
Referred To · Aug 19, 2025 · 1,636 Bills

Actions

H.R. 4993 has taken 4 actions since Aug 19, 2025, the latest on Dec 10, 2025.

ChamberAction
Dec 10, 2025
House
Committee Consideration and Mark-up Session HeldWays and Means Committee
Dec 10, 2025
House
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.Ways and Means Committee
Aug 19, 2025
House
Introduced in House
Aug 19, 2025
House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Energy and Commerce Committee

Votes

H.R. 4993 has not gone to a roll call.

3 bills are related to H.R. 4993.

Titles

H.R. 4993 goes by 3 titles, 1 of them short titles.

  • To amend title XVIII of the Social Security Act to provide coverage of external infusion pumps and non-self-administrable home infusion drugs under the Medicare program. — Official Title as Introduced
  • Joe Fiandra Access to Home Infusion Act of 2025 — Display Title
  • Joe Fiandra Access to Home Infusion Act of 2025 — Short Title(s) as Introduced

Lobbying

5 clients hired 5 firms and 10 registered lobbyists who named H.R. 4993 in 14 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Medicare/Medicaid, Health Issues, Pharmacy, Trade (domestic/foreign), Marine/Maritime/Boating/Fisheries, Tariff (miscellaneous tariff bills), Budget/Appropriations.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
CHIESI USA, INC.Rare disease medicinesNorth Carolina14$210K
ALNYLAM PHARMACEUTICALS, INC.Pharmaceutical manufacturerMassachusetts14
WELLSKYHealth care technology companyKansas12$180K
NATIONAL ASSOCIATION OF WATERFRONT EMPLOYERSThe National Association of Waterfront Employers (NAWE) is the voice of the U.S. marine teVirginia12$60K
UCB, INC.California12

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
ALNYLAM PHARMACEUTICALS, INC.ALNYLAM PHARMACEUTICALS, INC.2026 second_quarter$450K2nd Quarter - Report
ALNYLAM PHARMACEUTICALS, INC.ALNYLAM PHARMACEUTICALS, INC.2026 first_quarter$430K1st Quarter - Report
ALNYLAM PHARMACEUTICALS, INC.ALNYLAM PHARMACEUTICALS, INC.2025 fourth_quarter$390K4th Quarter - Report
ALNYLAM PHARMACEUTICALS, INC.ALNYLAM PHARMACEUTICALS, INC.2025 third_quarter$390K3rd Quarter - Report
UCB, INC.UCB, INC.2025 fourth_quarter$350K4th Quarter - Report
UCB, INC.UCB, INC.2025 third_quarter$340K3rd Quarter - Report
WELLSKYDB3, LLC (FKA THE DASCHLE GROUP)2026 first_quarter$90K1st Quarter - Report
WELLSKYDB3, LLC (FKA THE DASCHLE GROUP)2025 fourth_quarter$90K4th Quarter - Report
CHIESI USA, INC.SPLITOAK STRATEGIES LLC2026 second_quarter$60K2nd Quarter - Report
CHIESI USA, INC.SPLITOAK STRATEGIES LLC2026 first_quarter$50K1st Quarter - Report
CHIESI USA, INC.SPLITOAK STRATEGIES LLC2025 fourth_quarter$50K4th Quarter - Report
CHIESI USA, INC.SPLITOAK STRATEGIES LLC2025 third_quarter$50K3rd Quarter - Report
NATIONAL ASSOCIATION OF WATERFRONT EMPLOYERSBECKER & POLIAKOFF, P.A.2025 second_quarter$30K2nd Quarter - Report
NATIONAL ASSOCIATION OF WATERFRONT EMPLOYERSBECKER & POLIAKOFF, P.A.2025 first_quarter$30K1st Quarter - Report

Classification

The Congressional Research Service files H.R. 4993 under Health, one of its 31 policy areas, and gives it 5 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 4993’s is Health.

hr4993/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

H.R. 4993 carries 5 of CRS’s legislative subjects, from Health care coverage and access to Prescription drugs.

hr4993/subjects.txt
Health care coverage and accessHealth technology, devices, suppliesHome and outpatient careMedicarePrescription drugs

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 4993, as entered in the Congressional Record.

[Congressional Record Volume 171, Number 139 (Tuesday, August 19, 2025)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. FITZPATRICK:H.R. 4993.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 18[Page H3703]

Source: congress.gov · legiscan.com